PE Pharma Services Dealmaking Set to Accelerate
Despite continued buzz around pharma services within the PE healthcare ecosystem, deal activity in the sector remained flat in Q2 2024, with an estimated 72 deals announced or closed in the quarter. However, the tide is turning.
In this brief update, lead healthcare analyst Rebecca Springer predicts a gradual acceleration in deal activity will materialize starting in Q3 as the healthcare PE industry continues to pivot away from care delivery and toward the life sciences. Prices are elevated for good assets, and we believe the momentum behind pharma services will continue to build over the coming years as firms become increasingly comfortable investing in life sciences and companies work through some current volatility in underlying financials.